Peter Hillmen
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research 216
- Hemoglobinopathies and Related Disorders 36
- Hematology top 0.05%
- Blood groups and transfusion 60
- Chronic Myeloid Leukemia Treatments 33
- Immunology top 0.05%
- Complement system in diseases 119
- Immunodeficiency and Autoimmune Disorders 82
- Nephrology top 0.05%
- Renal Diseases and Glomerulopathies 46
- Pathology and Forensic Medicine top 0.02%
- Lymphoma Diagnosis and Treatment 146
- Co-authors
- Russell P. RotherStephen J. RichardsThomas J. KippsMonica BesslerLucio LuzzattoMichael HallekEmili MontserratAndy C. Rawstron
- Cited by
- GeneticsHematologyImmunology
- Journals
- Blood (147 papers)British Journal of Haematology (36 papers)Journal of Clinical Oncology (33 papers)
- Partner nations
- United KingdomUnited StatesItaly
In The Last Decade
Peter Hillmen
336 papers receiving 22.0k citations
Hit Papers
Peers
Comparison fields: 5 of 140
- Genetics 14.2k
- Hematology 6.6k
- Immunology 12.1k
- Nephrology 3.9k
- Pathology and Forensic Medicine 9.3k
Countries citing papers authored by Peter Hillmen
This map shows the geographic impact of Peter Hillmen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Hillmen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Hillmen more than expected).
Fields of papers citing papers by Peter Hillmen
This network shows the impact of papers produced by Peter Hillmen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Hillmen. The network helps show where Peter Hillmen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Peter Hillmen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 35 | |
| 2 | 2022 | 43 | |
| 3 | Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia breakdown → | 2022 | 146 |
| 4 | 2021 | 4 | |
| 5 | 2021 | 74 | |
| 6 | 2020 | 33 | |
| 7 | 2020 | 47 | |
| 8 | 2019 | 144 | |
| 9 | 2019 | 2 | |
| 10 | 2018 | 63 | |
| 11 | 2016 | 95 | |
| 12 | 2013 | 315 | |
| 13 | 2013 | 58 | |
| 14 | 2011 | 347 | |
| 15 | 2007 | 408 | |
| 16 | 2007 | 457 | |
| 17 | 2007 | 92 | |
| 18 | 2005 | 44 | |
| 19 | 2005 | 165 | |
| 20 | 2000 | 111 |
About Peter Hillmen
Peter Hillmen is a scholar working on Genetics, Hematology, Immunology, Pathology and Forensic Medicine and Nephrology, having authored 346 papers that have together received 22.5k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (216 papers), Lymphoma Diagnosis and Treatment (146 papers), Complement system in diseases (119 papers), Immunodeficiency and Autoimmune Disorders (82 papers), Blood groups and transfusion (60 papers), Renal Diseases and Glomerulopathies (46 papers), Hemoglobinopathies and Related Disorders (36 papers) and Chronic Myeloid Leukemia Treatments (33 papers). The work is most often cited by research in Genetics (14.2k citations), Hematology (6.6k citations), Immunology (12.1k citations), Nephrology (3.9k citations) and Pathology and Forensic Medicine (9.3k citations). Peter Hillmen has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Russell P. Rother, Stephen J. Richards, Thomas J. Kipps, Monica Bessler, Lucio Luzzatto, Michael Hallek, Emili Montserrat, Andy C. Rawstron, Michael J. Keating and Leonard Bell. Their work appears in journals such as Blood, British Journal of Haematology, Journal of Clinical Oncology, Leukemia and New England Journal of Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.